Arthritis Monoclonal Antibodies Market Advance Technology, Business Overview, Forecast 2033

Overview and Scope

Arthritis monoclonal antibodies refer to a class of sophisticated and useful biological medicines used to treat rheumatoid arthritis and other immune-mediated inflammatory conditions. They inhibit the inflammatory protein interleukin-6, which reduces arthritis-related joint pain and swelling as well as other inflammation-related symptoms. In order to prevent the body from rejecting the new organ after surgery, they reduce the body's defense mechanism.

Sizing and Forecast

The arthritis monoclonal antibodies market size has grown strongly in recent years. It will grow from $58.09 billion in 2023 to $62.29 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%.  The growth in the historic period can be attributed to rising prevalence of arthritis, increasing awareness of arthritis monoclonal antibodies, expanding range of approved arthritis monoclonal antibodies, government support for research and development, increased investment from pharmaceutical companies.

The arthritis monoclonal antibodies market size is expected to see strongly grown in the next few years. It will grow to $83.76 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%.  The growth in the forecast period can be attributed to combination therapies, expanding indications, patient preference, increased healthcare spending. Major trends in the forecast period include biosimilars and biobetters, targeted therapies, homecare administration, real-world evidence, cost and access considerations, advancements in drug delivery.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report

Segmentation & Regional Insights

The arthritis monoclonal antibodies market covered in this report is segmented –
1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima

2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications

3) By End-Use: Hopitals, Research Institutes, Other End-Users

North America was the largest region in the arthritis monoclonal antibodies market in 2023. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3449&type=smp

Major Driver Impacting Market Growth

The increasing prevalence of arthritis globally has contributed to the growth of the arthritis monoclonal antibody market. According to the Global RA Network, in 2021, Over 350 million individuals worldwide suffer from arthritis and osteoarthritis is the most common form of arthritis followed by gout, fibromyalgia, and rheumatoid arthritis. According to WHO, the prevalence of rheumatoid arthritis varies between 0.3% and 1%, and the worldwide estimates of osteoarthritis include 9.6% of men and 18% of women. The increased prevalence of arthritis and the demand for personalized medicine are increasing the demand for the market.

Key Industry Players

Major companies operating in the arthritis monoclonal antibodies market include  Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca plc, Mylan N.V., Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.

The arthritis monoclonal antibodies market report table of contents includes:
1. Executive Summary

2. Market Characteristics

3. Market Trends And Strategies

4. Impact Of COVID-19

5. Market Size And Growth

6. Segmentation

7. Regional And Country Analysis

……….

27. Competitive Landscape And Company Profiles

28. Key Mergers And Acquisitions

29. Future Outlook and Potential Analysis

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model